Fig. 5.

Systemic administration of WP1066 inhibits growth of intracranial BTSC73 xenografts. (A) STAT3 phosphorylation was dramatically reduced in BTSC xenografts after administration of WP1066 ([i, iv] human-specific nucleolin immunostaining in vehicle- and WP1066-treated mice; [ii, iii] phospho-STAT3 Y705 staining in vehicle- and [v, vi] WP1066-treated mice). (B) The percentage of TUNEL staining apoptotic cells was also significantly increased in WP1066-treated mice (P = .0002, Student's t-test). (C) A course of 4 weeks of thrice-weekly injections of WP1066 increased median survival of BTSC73 xenograft mice from 34 to 43 days (P = .033, log-rank test).